A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects with Lupus Membranous Nephropathy (LMN)
Principal Investigator: Vimal Derebail, MD, MPH
Sponsor: Gilead Sciences, Inc.
Age Range: 18-75
Purpose: To test two investigational drugs (Filgotinib and GS-9876) in patients with Class V (membranous) lupus of the kidney to see if they are successful in decreasing the amount of protein lost in the urine (proteinuria).
Study Procedures: Filgotinib and GS-9876 are both oral medications. Participants will be blinded as to which medication they are taking and may be switched after 16 weeks if significant decrease in proteinuria is not accomplished.
Participation: Participation in the study will last approximately 1 year.
For more information, please contact:
Brenda Meier, RN